Cosmetic procedures now use fat from deceased donors. Products such as AlloClae and Renuva, derived from processed human adipose tissue, are being injected into patients seeking volume restoration and body contouring without the need for surgery. The fat is harvested from abdominal cells collected by tissue banks during organ and tissue donation, then purchased and processed by companies for aesthetic use.
Minimal downtime, maximum appeal
The primary draw of these injections is the promise of a quick, non-surgical route to a fuller physique. Dr Douglas Steinbrech, a plastic surgeon at the Alpha Male clinic in Manhattan who has championed the use of AlloClae, described it as a “gamechanger”. He told the Guardian that recipients “don’t need surgery. They don’t need general anesthesia. They don’t have recovery, and the pain from all that.” The lack of downtime suits a clientele that cannot afford to lose productivity. According to the Guardian, plastic surgeons who completed a combined 75 procedures with AlloClae since its launch in early 2024 have described “wealthy executives and corporate types, booking 6am visits so they could make it to work by 7”, using the filler to improve how they look in work clothes.
The procedures are part of a wider trend in so-called “kooky” cosmetic treatments, including foot filler, vampire facelifts and “pokertox” – injectables used by poker players to suppress facial expressions. But the use of cadaver fat, sometimes dubbed “zombie filler” or “necrocosmetics”, has attracted particular attention. AlloClae, made by Tiger Aesthetics, is a structural adipose filler processed to retain the natural extracellular matrix, growth factors and collagen, and is intended for body contouring in areas such as the buttocks, hips and breasts. Renuva, developed by MTF Biologics, is an allograft adipose matrix used for smaller volume restoration in the face, hands and body. Both are marketed as ready-to-use, off-the-shelf alternatives to autologous fat transfer, which requires liposuction and a recovery period.
The rise of GLP-1 weight-loss drugs such as Ozempic, Wegovy and Mounjaro is fuelling demand. Dramatic weight loss can leave patients with hollowed cheeks, often termed “Ozempic face”, and loss of volume elsewhere. The Guardian noted that people “want to be skinny, but nobody wants a hollow face or a flat ass”, creating a vicious cycle in which patients shed fat only to pay for it to be restored. The trend also intersects with “looksmaxxing” and the promotion of idealised male physiques, with men seeking pectoral and bicep enhancement.
The ethical tightrope of donor consent
The use of donated fat for cosmetic purposes raises profound ethical questions about whether donors understand how their remains may be used. When individuals consent to organ and tissue donation, tissue banks often collect abdominal fat cells as part of the process. Companies such as Tiger Aesthetics and MTF Biologics then purchase that fat for processing. Tiger Aesthetics states that its injectable AlloClae is sourced from tissue “consented to for aesthetic use”, and MTF Biologics says the same for its product.
Yet a 2012 investigation indicated that tissue bank solicitors told potential donors that their tissue might be used for cosmetic surgery only 29% of the time. The figure has been cited repeatedly as evidence that the consent process is flawed. Although the fat is processed and sterilised, the question remains: would the donor have agreed if they had known their belly fat could end up rounding out someone else’s buttocks or breasts? The Guardian noted that this is not the first time donated tissue has been used for cosmetic surgery, but the practice has fuelled “longstanding concerns” about informed consent.
From a bioethical perspective, the primary focus is on harm minimisation to patients. Cadavers are no longer living and therefore cannot be harmed by the use of their tissue, while recipients stand to gain aesthetic benefits. Nevertheless, some donors express unease that their gift could be used for elective vanity procedures rather than life-saving treatments. Proponents point out that a single donor can contribute to multiple lives through organ, eye and tissue donation, and that fat is just one of many potential uses.
A deeper ethical problem, the Guardian argued, is the “moral hierarchy of elective vanity procedures versus life-saving surgeries”. The real issue, it suggested, may not be that we are “stripping dead people for parts” but rather what we are using those parts for. The queasiness many feel reflects “conservative attitudes toward cosmetic procedures” and a lingering discomfort with the commodification of human remains.
Societal implications: capitalism, ageing and the pursuit of perfection
The aesthetics of capitalism play a significant role in the growing popularity of these procedures. Minimal downtime means patients can return to work quickly, a priority for those who measure their worth by productivity. The Guardian termed this the “politics of beauty in the west”, which continues to shape who is allowed to be successful. “Zombie filler” supports a lifestyle in which wealthy individuals can make significant changes to their appearance with no recovery time to interrupt the capitalist processes that demand the physical perfection they are seeking.
The drive for perpetual youth is another undercurrent. Anti-ageing is a billion-dollar business, and those seeking cosmetic procedures are skewing younger. Social media and celebrity culture are influencing a new generation to opt for subtle or preventative enhancements. The Guardian pointed out the “biggest irony” of the trend: in the pursuit of immortality, people have come back to the thing they were running away from – death. “It’s not the cadavers that are scariest,” the article concluded; “it’s our increasing rejection of our bodies’ natural processes, and the ways we’re willing to commercialize everything in order to feed that rejection.”
In the UK, concerns about regulation are mounting. While AlloClae is regulated by the Food and Drug Administration in the United States, calls have been made for mandatory medical qualifications for practitioners, formal licensing of clinics and public awareness campaigns about the risks. Potential complications include cystic or nodule formations, pain, infection and allergic responses. The UK’s non-surgical aesthetics market has been described as a “wild west” of untrained, unlicensed individuals offering procedures in unsuitable locations. Surgical fat transfer in the UK typically costs between £3,000 and £8,000.
Fat grafting itself is not new: early attempts date back to the late 19th century, and standardised techniques were developed in the 1990s by Dr Sydney Coleman. A moratorium on fat grafting to the breasts was imposed by the American Society of Plastic Surgeons in the late 1980s over concerns about fat necrosis mimicking breast cancer on imaging, but it was reversed in 2008. What is new is the widespread commercialisation of donor fat as a cosmetic commodity, a development that the Guardian observed has created “a society where everyone is insecure about their bodies and the goalpost of beauty and physical fitness moves constantly. So if consenting to being an organ donor means one day your stubborn belly fat could end up rounding out someone else’s botched boob job, then so be it.”